Welldoc announced today that it received another FDA 510(k) clearance for its BlueStar diabetes treatment platform.
Columbia, Maryland-based Welldoc’s new clearance for BlueStar — the ninth in total — expands insulin dosing support to most types of insulin, including bolus and premixed insulin titration for type 2 diabetes.
Get the full story at our sister site, Drug Delivery Business News.